Athira Pharma (NASDAQ: ATHA)
$1.92
(-4.5%)
-$0.09
Price as of April 25, 2024, 4:00 p.m. ET
Athira Pharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Athira Pharma Company Info
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.
News & Analysis
Featured Article
Why Athira Pharma Stock Imploded Today
Its mid-stage clinical trial failed to help patients with Alzheimer's.
Alex Carchidi | Jun 22, 2022
Featured Article
Why Shares of Athira Pharma Are Climbing Today
The clinical trial for its Alzheimer's drug is one step closer to completion.
Jason Hawthorne | Oct 22, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.